PMID- 12430001
OWN - NLM
STAT- MEDLINE
DCOM- 20030514
LR  - 20041117
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 10
IP  - 6
DP  - 2002 Dec
TI  - Interleukin-12-mediated induction of systemic immunity in the periphery and 
      recruitment of activated T cells into the brain produce limited antitumor effects 
      compared with interleukin-2.
PG  - 741-7
AB  - Interleukin-12 (IL-12) stimulates the type 1 helper T (Th1) cell responses and 
      augments antitumor immunity. We examined possible antitumor effects of IL-12 
      secreted intracerebrally (i.c.) and/or subcutaneously (s.c.) in an experimental 
      glioblastoma model and compared the effects with those of IL-2. Rat 9L 
      gliosarcoma cells retrovirally transduced with the IL-12 or IL-2 gene (9L/IL-12 
      and 9L/IL-2, respectively) were completely rejected when they were s.c. 
      inoculated. The transduced cells, implanted i.c., developed progressive brain 
      tumors at reduced rates compared with 9L brain tumors and the growth retardation 
      of 9L/IL-2 tumors was greater than that of 9L/IL-12 tumors. When rats were s.c. 
      immunized with either 9L/IL-12 or 9L/IL-2 cells, the growth of 9L brain tumors 
      developed in the rats was suppressed compared with that of 9L tumors in naive 
      rats. Among various combinations of simultaneous inoculations of cytokine 
      producers s.c. and i.c., 9L/IL-2 but not 9L/IL-12 cells inoculated i.c. were 
      rejected when the rats were s.c. immunized with either 9L/IL-12 or 9L/IL-2 cells. 
      The synergistic antitumor effects induced were correlated with the infiltration 
      levels of CD8+ and CD4+ T cells into brain tumors. Tumor-specific cytotoxic 
      activity was induced in the rats immunized s.c. with 9L/IL-2 but not fully in the 
      rats with 9L/IL-12 cells. These results collectively suggest that the antitumor 
      activity with IL-2 was superior to IL-12 both in the induction of cytotoxic T 
      cells and in the recruitment of activated T cells into brain tumors.
FAU - Iwadate, Yasuo
AU  - Iwadate Y
AD  - Department of Neurological Surgery, Chiba University Graduate School of Medicine, 
      Chuo-ku, Chiba 260-8670, Japan. iwadate@med.m.chiba-u.ac.jp
FAU - Namba, Hiroki
AU  - Namba H
FAU - Sakiyama, Shigeru
AU  - Sakiyama S
FAU - Yamaura, Akira
AU  - Yamaura A
FAU - Tagawa, Masatoshi
AU  - Tagawa M
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-2)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Brain Neoplasms/*drug therapy
MH  - Cell Movement/drug effects
MH  - Humans
MH  - Immunity/drug effects
MH  - Interleukin-12/*pharmacology
MH  - Interleukin-2/*pharmacology
MH  - Mice
MH  - Rats
MH  - T-Lymphocytes/drug effects
MH  - Transduction, Genetic
EDAT- 2002/11/14 04:00
MHDA- 2003/05/15 05:00
CRDT- 2002/11/14 04:00
PHST- 2002/11/14 04:00 [pubmed]
PHST- 2003/05/15 05:00 [medline]
PHST- 2002/11/14 04:00 [entrez]
PST - ppublish
SO  - Int J Mol Med. 2002 Dec;10(6):741-7.